Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 4

BIOSANTE Form 4 July 31, 2008	PHARMACEUT	TICALS	INC									
FORM									-	PPROVAL		
-	UNITED	STATES		ITIES A hington,			NGE (COMMISSION	OMB Number:	3235-0287		
Check this box if no longer subject to Section 16. Form 4 or				GES IN I SECUR		[CIA]	LOW	Expires:		rs per		
may conti	Form 5 obligations may continue.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,See InstructionSection 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type R	Responses)											
			Symbol	2. Issuer Name and Ticker or Trading Symbol BIOSANTE PHARMACEUTICALS					5. Relationship of Reporting Person(s) to Issuer			
			INC [BF	PAX]				(Check all applicable)				
(1			(Month/D	3. Date of Earliest Transaction(Month/Day/Year)07/29/2008				X Director 10% Owner X Officer (give title Other (specify below) below) Vice Chairman, President & CEO				
Filed(Mc				mendment, Date Original /Ionth/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
LINCOLNS	HIRE, IL 60069							Person	Note than one R	porting		
(City)	(State)	(Zip)	Table	e I - Non-D	erivative	Securi	ities Acc	uired, Disposed o	f, or Beneficial	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Dat (Month/Day/Year)	Execution any	emed on Date, if Day/Year)		on(A) or D (D) (Instr. 3,	ispose 4 and (A) or	d of 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common Stock	07/29/2008			Code V X	500	(D) A	Price \$ 2.15	187,067	Ι	By Trust		
Common Stock								100	Ι	By Child		
Common Stock								100	Ι	By Child		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number prof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercis Expiration Dat (Month/Day/Y	e	7. Title and A Underlying S (Instr. 3 and	Securities	8. P Der Sec (Ins
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Warrant (right to buy)	\$ 2.15	07/29/2008		Х	500	08/04/2003	08/03/2008	Common Stock	500	

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
SIMES STEPHEN M 111 BARCLAY BOULEVARD LINCOLNSHIRE, IL 60069	Х		Vice Chairman, President & CEO			

Signatures

/s/ Stephen M. Simes	07/31/2008			
<u>**</u> Signature of Reporting Person	Date			

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.